Phase 2/3 clinical trial assessing INO-4201
Latest Information Update: 16 Jan 2025
At a glance
- Drugs INO-4201 (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 09 Jan 2025 According to INOVIO pharmaceuticals media release, company anticipate to finalize Phase 2 trial protocols and seek funding to support trial activities in 2025.
- 21 Nov 2024 According to INOVIO pharmaceuticals media release, company has scheduled a meeting with the FDA in the fourth quarter of 2024 to discuss the proposed Phase 2 trial design.
- 14 Aug 2024 New trial record